So we’re looking for ways to improve the outcomes with lutetium-based PSMA therapy. And it’s been shown with studies such as VISION, where there was an improved PSA response rate, as well as radiographic progression-free survival in patients who received combination therapy with enzalutamide and lutetium versus enzalutamide alone. So ARV766 is an antigen receptor degrader, which potentially increases PSMA expression...
So we’re looking for ways to improve the outcomes with lutetium-based PSMA therapy. And it’s been shown with studies such as VISION, where there was an improved PSA response rate, as well as radiographic progression-free survival in patients who received combination therapy with enzalutamide and lutetium versus enzalutamide alone. So ARV766 is an antigen receptor degrader, which potentially increases PSMA expression. And this trial is designed to look at that question, whether giving ARV766 will actually increase the efficacy. It’s a small study, but whether we want to go forward and see if there is a signal that we can work with that shows that there’s improved outcomes rate.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
